Address
60 rue de Wattignies
Paris, IF 75012
France
Phone
33 1 40 26 04 70
Website
Sector
Healthcare
Industry
Medical - Pharmaceuticals
Employees
100
First IPO Date
February 13, 2014
| Name | Title | Pay | Year Born |
| Laurent Levy | Co-Founder, President of the Executive Board & Chief Executive Officer | 844,959 | 1973 |
| Anne-Juliette Hermant | Chief People Officer & Member of Executive Board | 414,440 | 1974 |
| Bart Van Rhijn | Chief Financial & Business Officer and Member of Executive Board | 600,232 | 1974 |
| Louis Kayitalire | Chief Medical Officer & Member of Executive Board | 603,196 | 1959 |
| Margaret Galluzzi | Vice President & Global Head of Clinical Operations | 0 | N/A |
| Brandon Owens | Vice President of Strategic Marketing & Corporate Communication | 0 | N/A |
| Earl J. Bergey | Co-Founder | 0 | 1955 |
| Anne-Sophie Lariviere | Chief Product Innovation & Delivery Officer | 0 | N/A |
| Leonard A. Farber | Chief Clinical and Medical Affairs Officer & Chairman of the Scientific Advisory Board | 0 | N/A |
Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is based in Paris, France.